1
|
Colomo S, Ros-Pardo D, Oltra SS, Gomez-Puertas P, Sarrio D, Moreno-Bueno G. Structural and functional insights into GSDMB isoforms complex roles in pathogenesis. Cell Cycle 2023; 22:2346-2359. [PMID: 38037340 PMCID: PMC10730220 DOI: 10.1080/15384101.2023.2287933] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2023] [Accepted: 11/20/2023] [Indexed: 12/02/2023] Open
Abstract
SHADSGasdermins (GSDMs) have garnered significant scientific interest due to their protective and detrimental roles in innate immunity, host defense, inflammation, and cancer alongside with other pathologies. While GSDMs are mostly recognized as key effectors of a lytic type of pro-inflammatory cell death known as pyroptosis, they do also take part in other cell death processes (NETosis, secondary necrosis, or apoptosis) and exhibit cell-death independent functions depending on the cellular context. Among GSDMs, Gasdermin B (GSDMB) pyroptotic capacity has been a subject of conflicting findings in scientific literature even when its processing, and subsequent activation, by Granzyme A (GZMA) was decoded. Nevertheless, recent groundbreaking publications have shed light on the crucial role of alternative splicing in determining the pyroptotic capacity of GSDMB isoforms, which depends on the presence of exon 6-derived elements. This comprehensive review pays attention to the relevant structural differences among recently crystalized GSDMB isoforms. As a novelty, the structural aspects governing GSDMB isoform susceptibility to GZMA-mediated activation have been investigated. By elucidating the complex roles of GSDMB isoforms, this review aims to deepen the understanding of this multifunctional player and its potential implications in disease pathogenesis and therapeutic interventions. [Figure: see text].
Collapse
Affiliation(s)
- Sara Colomo
- Biochemistry Department, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas ‘Sols-Morreale’ (IIBm-CISC), Madrid, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
| | - David Ros-Pardo
- Grupo de modelado molecular, Centro de Biología Molecular Severo Ochoa, CBMSO (CSIC-UAM), Madrid, Spain
| | - Sara S Oltra
- Biochemistry Department, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas ‘Sols-Morreale’ (IIBm-CISC), Madrid, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
- Laboratorio de Investigación Traslacional, Fundación MD Anderson Internacional (FMDA), Madrid, Spain
| | - Paulino Gomez-Puertas
- Grupo de modelado molecular, Centro de Biología Molecular Severo Ochoa, CBMSO (CSIC-UAM), Madrid, Spain
| | - David Sarrio
- Biochemistry Department, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas ‘Sols-Morreale’ (IIBm-CISC), Madrid, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
| | - Gema Moreno-Bueno
- Biochemistry Department, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas ‘Sols-Morreale’ (IIBm-CISC), Madrid, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain
- Laboratorio de Investigación Traslacional, Fundación MD Anderson Internacional (FMDA), Madrid, Spain
| |
Collapse
|
2
|
Albanell-Fernández M, Oltra SS, Orts-Arroyo M, Ibarrola-Villava M, Carrasco F, Jiménez-Martí E, Cervantes A, Castro I, Martínez-Lillo J, Ribas G. RUNAT-BI: A Ruthenium(III) Complex as a Selective Anti-Tumor Drug Candidate against Highly Aggressive Cancer Cell Lines. Cancers (Basel) 2022; 15:cancers15010069. [PMID: 36612065 PMCID: PMC9817854 DOI: 10.3390/cancers15010069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2022] [Revised: 12/19/2022] [Accepted: 12/20/2022] [Indexed: 12/24/2022] Open
Abstract
Ruthenium compounds have demonstrated promising activity in different cancer types, overcoming several limitations of platinum-based drugs, yet their global structure-activity is still under debate. We analyzed the activity of Runat-BI, a racemic Ru(III) compound, and of one of its isomers in eight tumor cell lines of breast, colon and gastric cancer as well as in a non-tumoral control. Runat-BI was prepared with 2,2'-biimidazole and dissolved in polyethylene glycol. We performed assays of time- and dose-dependent viability, migration, proliferation, and expression of pro- and antiapoptotic genes. Moreover, we studied the growth rate and cell doubling time to correlate it with the apoptotic effect of Runat-BI. As a racemic mixture, Runat-BI caused a significant reduction in the viability and migration of three cancer cell lines from colon, gastric and breast cancer, all of which displayed fast proliferation rates. This compound also demonstrated selectivity between tumor and non-tumor lines and increased proapoptotic gene expression. However, the isolated isomer did not show any effect. Racemic Runat-BI is a potential drug candidate for treatment of highly aggressive tumors. Further studies should be addressed at evaluating the role of the other isomer, for a more precise understanding of its antitumoral potential and mechanism of action.
Collapse
Affiliation(s)
- Marta Albanell-Fernández
- INCLIVA Biomedical Research Institute, Hospital Clínico Universitario Valencia, University of Valencia, 46010 Valencia, Spain
| | - Sara S. Oltra
- INCLIVA Biomedical Research Institute, Hospital Clínico Universitario Valencia, University of Valencia, 46010 Valencia, Spain
| | - Marta Orts-Arroyo
- Instituto de Ciencia Molecular (ICMol)/Departament de Química Inorgànica, University of Valencia, 46980 Valencia, Spain
| | - Maider Ibarrola-Villava
- INCLIVA Biomedical Research Institute, Hospital Clínico Universitario Valencia, University of Valencia, 46010 Valencia, Spain
- Center for Biomedical Network Research on Cancer (CIBERONC), 28029 Madrid, Spain
| | - Fany Carrasco
- INCLIVA Biomedical Research Institute, Hospital Clínico Universitario Valencia, University of Valencia, 46010 Valencia, Spain
- Center for Biomedical Network Research on Cancer (CIBERONC), 28029 Madrid, Spain
| | - Elena Jiménez-Martí
- INCLIVA Biomedical Research Institute, Hospital Clínico Universitario Valencia, University of Valencia, 46010 Valencia, Spain
- Center for Biomedical Network Research on Cancer (CIBERONC), 28029 Madrid, Spain
- Departament de Bioquímica i Biología Molecular, Facultat de Medicina, University of Valencia, 46010 Valencia, Spain
| | - Andrés Cervantes
- INCLIVA Biomedical Research Institute, Hospital Clínico Universitario Valencia, University of Valencia, 46010 Valencia, Spain
- Center for Biomedical Network Research on Cancer (CIBERONC), 28029 Madrid, Spain
| | - Isabel Castro
- Instituto de Ciencia Molecular (ICMol)/Departament de Química Inorgànica, University of Valencia, 46980 Valencia, Spain
| | - José Martínez-Lillo
- Instituto de Ciencia Molecular (ICMol)/Departament de Química Inorgànica, University of Valencia, 46980 Valencia, Spain
- Correspondence: (J.M.-L.); (G.R.); Tel.: +34-9635-44460 (J.M.-L.)
| | - Gloria Ribas
- INCLIVA Biomedical Research Institute, Hospital Clínico Universitario Valencia, University of Valencia, 46010 Valencia, Spain
- Center for Biomedical Network Research on Cancer (CIBERONC), 28029 Madrid, Spain
- Correspondence: (J.M.-L.); (G.R.); Tel.: +34-9635-44460 (J.M.-L.)
| |
Collapse
|
3
|
Mota A, Oltra SS, Selenica P, Moiola CP, Casas-Arozamena C, López-Gil C, Diaz E, Gatius S, Ruiz-Miro M, Calvo A, Rojo-Sebastián A, Hurtado P, Piñeiro R, Colas E, Gil-Moreno A, Reis-Filho JS, Muinelo-Romay L, Abal M, Matias-Guiu X, Weigelt B, Moreno-Bueno G. Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression. Oncogene 2022; 41:1835-1850. [PMID: 35145232 PMCID: PMC8956509 DOI: 10.1038/s41388-022-02221-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2021] [Revised: 01/12/2022] [Accepted: 01/27/2022] [Indexed: 12/12/2022]
Abstract
Analyzing different tumor regions by next generation sequencing allows the assessment of intratumor genetic heterogeneity (ITGH), a phenomenon that has been studied widely in some tumor types but has been less well explored in endometrial carcinoma (EC). In this study, we sought to characterize the spatial and temporal heterogeneity of 9 different ECs using whole-exome sequencing, and by performing targeted sequencing validation of the 42 primary tumor regions and 30 metastatic samples analyzed. In addition, copy number alterations of serous carcinomas were assessed by comparative genomic hybridization arrays. From the somatic mutations, identified by whole-exome sequencing, 532 were validated by targeted sequencing. Based on these data, the phylogenetic tree reconstructed for each case allowed us to establish the tumors’ evolution and correlate this to tumor progression, prognosis, and the presence of recurrent disease. Moreover, we studied the genetic landscape of an ambiguous EC and the molecular profile obtained was used to guide the selection of a potential personalized therapy for this patient, which was subsequently validated by preclinical testing in patient-derived xenograft models. Overall, our study reveals the impact of analyzing different tumor regions to decipher the ITGH in ECs, which could help make the best treatment decision.
Collapse
Affiliation(s)
- Alba Mota
- MD Anderson International Foundation, 28033, Madrid, Spain.,Biochemistry Department, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas 'Alberto Sols' (CSIC-UAM), IdiPaz, 28029, Madrid, Spain
| | - Sara S Oltra
- MD Anderson International Foundation, 28033, Madrid, Spain.,Biochemistry Department, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas 'Alberto Sols' (CSIC-UAM), IdiPaz, 28029, Madrid, Spain.,Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029, Madrid, Spain
| | - Pier Selenica
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Cristian P Moiola
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029, Madrid, Spain.,Biomedical Research Group in Gynecology, Vall Hebron Institute of Research, Universitat Autònoma de Barcelona, 08035, Barcelona, Spain
| | - Carlos Casas-Arozamena
- Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706, Santiago de Compostela, Spain
| | - Carlos López-Gil
- Biomedical Research Group in Gynecology, Vall Hebron Institute of Research, Universitat Autònoma de Barcelona, 08035, Barcelona, Spain
| | - Eva Diaz
- MD Anderson International Foundation, 28033, Madrid, Spain
| | - Sonia Gatius
- Department of Pathology, Hospital U Arnau de Vilanova, University of Lleida, IRBLLEIDA, Lleida, Spain
| | | | - Ana Calvo
- Department of Gynecology, Hospital U Arnau de Vilanova, IRBLLEIDA, Lleida, Spain
| | - Alejandro Rojo-Sebastián
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029, Madrid, Spain.,Biomedical Research Group in Gynecology, Vall Hebron Institute of Research, Universitat Autònoma de Barcelona, 08035, Barcelona, Spain.,MD Anderson Cancer Center, Madrid, Spain
| | - Pablo Hurtado
- Roche-Chus Joint Unit, Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, 15706, Santiago de Compostela, Spain
| | - Roberto Piñeiro
- Roche-Chus Joint Unit, Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, 15706, Santiago de Compostela, Spain
| | - Eva Colas
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029, Madrid, Spain.,Biomedical Research Group in Gynecology, Vall Hebron Institute of Research, Universitat Autònoma de Barcelona, 08035, Barcelona, Spain
| | - Antonio Gil-Moreno
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029, Madrid, Spain.,Biomedical Research Group in Gynecology, Vall Hebron Institute of Research, Universitat Autònoma de Barcelona, 08035, Barcelona, Spain.,Gynaecological Department, Vall Hebron University Hospital, 08035, Barcelona, Spain
| | - Jorge S Reis-Filho
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Laura Muinelo-Romay
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029, Madrid, Spain.,Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706, Santiago de Compostela, Spain
| | - Miguel Abal
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029, Madrid, Spain.,Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706, Santiago de Compostela, Spain
| | - Xavier Matias-Guiu
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029, Madrid, Spain.,Department of Pathology, Hospital U Arnau de Vilanova, University of Lleida, IRBLLEIDA, Lleida, Spain.,Departments of Pathology, Hospital U. de Bellvitge, Universities of Lleida and Barcelona, IDIBELL Lleida and Barcelona, Spain
| | - Britta Weigelt
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
| | - Gema Moreno-Bueno
- MD Anderson International Foundation, 28033, Madrid, Spain. .,Biochemistry Department, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas 'Alberto Sols' (CSIC-UAM), IdiPaz, 28029, Madrid, Spain. .,Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029, Madrid, Spain.
| |
Collapse
|
4
|
García-Estévez L, Calvo I, Pérez S, Gallegos I, Díaz E, Sampayo-Cordero M, Oltra SS, Moreno-Bueno G. Predictive Role of Leptin Receptor (Ob-R) Overexpression in Patients with Early Breast Cancer Receiving Neoadjuvant Systemic Treatment. Cancers (Basel) 2021; 13:cancers13133269. [PMID: 34210055 PMCID: PMC8268260 DOI: 10.3390/cancers13133269] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2021] [Accepted: 06/24/2021] [Indexed: 12/12/2022] Open
Abstract
The primary aim of this retrospective study was to investigate the correlation between the immunohistochemical expression of Ob-R (leptin receptor) with pCR (pathological complete response) in early breast cancer patients receiving neoadjuvant systemic treatment (NST). A total of 100 women with breast cancer receiving NST (2017-2020) followed by surgical resection were retrospectively obtained. Demographic parameters and clinicopathological factors (e.g., treatment modalities, immunohistochemistry (IHC), and cancer subtype) were obtained from the patient's clinical records. In the analyzed breast cancer cohort, high expression of Ob-R was found in 52% of tumors and there was a significantly higher incidence in the HER2+ and TNBC subgroups. Overall, a significantly greater percentage of patients with Ob-R positive tumors achieved pCR compared with Ob-R negative patients (57.7% vs. 27.1%; p = 0.002). This result was observed in most breast cancer subtypes. In patients with HER2+ breast cancer, there was no difference in Ob-R expression in relation to the HR status. Ob-R cell positivity was significantly higher in younger breast cancer patients (p = 0.008), those who were premenopausal (p = 0.011), and in those with a BMI > 25 kg/m2 (p = 0.019). A significantly greater percentage of early breast cancer patients with Ob-R positive tumors achieved pCR compared with Ob-R negative patients. Furthermore, breast cancer patients with positive Ob-R expression were significantly younger than those with negative Ob-R expression. This association was not explained by differences in BMI between young and old patients.
Collapse
Affiliation(s)
- Laura García-Estévez
- Foundation MD Anderson International, C/Gómez Hemans 2, 28033 Madrid, Spain; (I.C.); (S.P.); (I.G.); (E.D.); (S.S.O.); (G.M.-B.)
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain
- Correspondence:
| | - Isabel Calvo
- Foundation MD Anderson International, C/Gómez Hemans 2, 28033 Madrid, Spain; (I.C.); (S.P.); (I.G.); (E.D.); (S.S.O.); (G.M.-B.)
| | - Silvia Pérez
- Foundation MD Anderson International, C/Gómez Hemans 2, 28033 Madrid, Spain; (I.C.); (S.P.); (I.G.); (E.D.); (S.S.O.); (G.M.-B.)
| | - Isabel Gallegos
- Foundation MD Anderson International, C/Gómez Hemans 2, 28033 Madrid, Spain; (I.C.); (S.P.); (I.G.); (E.D.); (S.S.O.); (G.M.-B.)
| | - Eva Díaz
- Foundation MD Anderson International, C/Gómez Hemans 2, 28033 Madrid, Spain; (I.C.); (S.P.); (I.G.); (E.D.); (S.S.O.); (G.M.-B.)
| | - Miguel Sampayo-Cordero
- Medica Scientia Innovation Research (MedSIR), 08018 Barcelona, Spain;
- Optimapharm, Biostatistics Department, Parc Bit Edifici Disset A2, 07121 Palma de Mallorca, Spain
| | - Sara S Oltra
- Foundation MD Anderson International, C/Gómez Hemans 2, 28033 Madrid, Spain; (I.C.); (S.P.); (I.G.); (E.D.); (S.S.O.); (G.M.-B.)
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain
- Biochemistry Department, Instituto de Investigaciones Biomédoicas ‘Alberto Sols’ (CSIC-UAM), Universidad Autónoma de Madrid (UAM), IdiPaz, 28029 Madrid, Spain
| | - Gema Moreno-Bueno
- Foundation MD Anderson International, C/Gómez Hemans 2, 28033 Madrid, Spain; (I.C.); (S.P.); (I.G.); (E.D.); (S.S.O.); (G.M.-B.)
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain
- Biochemistry Department, Instituto de Investigaciones Biomédoicas ‘Alberto Sols’ (CSIC-UAM), Universidad Autónoma de Madrid (UAM), IdiPaz, 28029 Madrid, Spain
| |
Collapse
|
5
|
Oltra SS, Peña-Chilet M, Martinez MT, Tormo E, Cejalvo JM, Climent J, Eroles P, Lluch A, Ribas G. miRNA Expression Analysis: Cell Lines HCC1500 and HCC1937 as Models for Breast Cancer in Young Women and the miR-23a as a Poor Prognostic Biomarker. Breast Cancer (Auckl) 2020; 14:1178223420977845. [PMID: 33311984 PMCID: PMC7716059 DOI: 10.1177/1178223420977845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/02/2020] [Accepted: 11/06/2020] [Indexed: 11/16/2022]
Abstract
PURPOSE The study of breast cancer nearly always involves patients close to menopause or older. Therefore, young patients are mostly underrepresented. Our aim in this study was to demonstrate biological differences in breast cancer of young people using as a model available cell lines derived from people with breast cancer younger than 35 years. METHODS Global miRNA expression was analyzed in breast cancer cells from young (HCC1500, HCC1937) and old patients (MCF-7, MDA-MB-231, HCC1806, and MDA-MB-468). In addition, it was compared with same type of results from patients. RESULTS We observed a differential profile for 155 miRNAs between young and older cell lines. We identified a set of 24 miRNA associated with aggressiveness that were regulating pluripotency of stem cell-related pathways. Combining the miRNA expression data from cell lines and breast cancer patients, 132 miRNAs were differently expressed between young and old samples, most of them previously found in cell lines. MiR-23a-downregulation was also associated with poor survival in young patients. CONCLUSIONS Our results suggest that HCC1500 and HCC1937 cell lines could be suitable cellular models for breast cancer affecting young women. The miR-23a-downregulation could have a potential role as a poor prognosis biomarker in this age group.
Collapse
Affiliation(s)
- Sara S Oltra
- Medical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain
| | - Maria Peña-Chilet
- Medical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain
| | - Maria T Martinez
- Medical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain
| | - Eduardo Tormo
- Medical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain.,Center for Biomedical Network Research on Cancer (CIBERONC), Valencia, Spain
| | - Juan Miguel Cejalvo
- Medical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain
| | - Joan Climent
- Medical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain
| | - Pilar Eroles
- Medical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain.,Center for Biomedical Network Research on Cancer (CIBERONC), Valencia, Spain
| | - Ana Lluch
- Medical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain.,Center for Biomedical Network Research on Cancer (CIBERONC), Valencia, Spain
| | - Gloria Ribas
- Medical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain.,Center for Biomedical Network Research on Cancer (CIBERONC), Valencia, Spain
| |
Collapse
|
6
|
Mota A, S Oltra S, Moreno-Bueno G. Insight updating of the molecular hallmarks in ovarian carcinoma. EJC Suppl 2020; 15:16-26. [PMID: 33240439 PMCID: PMC7573468 DOI: 10.1016/j.ejcsup.2019.11.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2019] [Revised: 10/17/2019] [Accepted: 11/16/2019] [Indexed: 12/31/2022] Open
Abstract
Background and purpose Ovarian cancer (OC) is the deadliest gynaecologic cancer characterised by a high heterogeneity not only at the clinical point of view but also at the molecular level. This review focuses on the new insights about the OC molecular classification. Materials and methods We performed a bibliographic search for different indexed articles focused on the new molecular classification of OC. All of them have been published in PubMed and included information about the most frequent molecular alterations in OC confirmed by omics approaches. In addition, we have extracted information about the role of liquid biopsy in the OC diagnosis and prognosis. Results New molecular insights into OC have allowed novel clinical entities to be defined. Among OC, high-grade serous ovarian carcinoma (HGSOC) which is the most common OC is characterised by omics approaches, mutations in TP53 and in other genes involved in the homologous recombination repair, especially BRCA1/2. Recent studies in HGSOC have allowed a new molecular classification in subgroups according to their mutational, transcriptional, methylation and copy number variation signatures with a real impact in the characterisation of new therapeutic targets for OC to be defined. Furthermore, despite the intrinsic intra-tumour heterogeneity, the advances in next generation sequencing (NGS) analyses of ascetic liquid from OC have opened new ways for its characterisation and treatment. Conclusions The advances in genomic approaches have been used for the identification of new molecular profiling techniques which define OC subgroups and has supposed advances in the diagnosis and in the personalised treatment of OC. Classification of ovarian cancer regarding to widespread genetic and genomic data. Highlighted role of p53 and BRCA1/2 in ovarian cancer for diagnosis and treatment. Intra-tumour genetic heterogeneity in ovarian cancer. Useful of liquid biopsy study in ovarian cancer diagnosis.
Collapse
Affiliation(s)
- Alba Mota
- Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas ‘Alberto Sols’ (CSIC-UAM), IdiPaz, MD Anderson International Foundation Madrid, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain
| | - Sara S Oltra
- Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas ‘Alberto Sols’ (CSIC-UAM), IdiPaz, MD Anderson International Foundation Madrid, Spain
| | - Gema Moreno-Bueno
- Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas ‘Alberto Sols’ (CSIC-UAM), IdiPaz, MD Anderson International Foundation Madrid, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain
- Corresponding author: Departamento de Bioquímica, Facultad de Medicina (UAM), Instituto de Investigaciones Biomédicas “Alberto Sols” CSIC-UAM, Arzobispo Morcillo 4, Madrid, 28029, Spain. Fax: +34 91-5854401.
| |
Collapse
|
7
|
Casas-Arozamena C, Díaz E, Moiola CP, Alonso-Alconada L, Ferreiros A, Abalo A, López Gil C, Oltra SS, de Santiago J, Cabrera S, Sampayo V, Bouso M, Arias E, Cueva J, Colas E, Vilar A, Gil-Moreno A, Abal M, Moreno-Bueno G, Muinelo-Romay L. Genomic Profiling of Uterine Aspirates and cfDNA as an Integrative Liquid Biopsy Strategy in Endometrial Cancer. J Clin Med 2020; 9:E585. [PMID: 32098121 PMCID: PMC7073542 DOI: 10.3390/jcm9020585] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2020] [Revised: 02/04/2020] [Accepted: 02/19/2020] [Indexed: 12/17/2022] Open
Abstract
The incidence and mortality of endometrial cancer (EC) have risen in recent years, hence more precise management is needed. Therefore, we combined different types of liquid biopsies to better characterize the genetic landscape of EC in a non-invasive and dynamic manner. Uterine aspirates (UAs) from 60 patients with EC were obtained during surgery and analyzed by next-generation sequencing (NGS). Blood samples, collected at surgery, were used for cell-free DNA (cfDNA) and circulating tumor cell (CTC) analyses. Finally, personalized therapies were tested in patient-derived xenografts (PDXs) generated from the UAs. NGS analyses revealed the presence of genetic alterations in 93% of the tumors. Circulating tumor DNA (ctDNA) was present in 41.2% of cases, mainly in patients with high-risk tumors, thus indicating a clear association with a more aggressive disease. Accordingly, the results obtained during the post-surgery follow-up indicated the presence of ctDNA in three patients with progressive disease. Moreover, 38.9% of patients were positive for CTCs at surgery. Finally, the efficacy of targeted therapies based on the UA-specific mutational landscape was demonstrated in PDX models. Our study indicates the potential clinical applicability of a personalized strategy based on a combination of different liquid biopsies to characterize and monitor tumor evolution, and to identify targeted therapies.
Collapse
Affiliation(s)
- Carlos Casas-Arozamena
- Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain; (C.C.-A.); (A.A.); (J.C.); (M.A.)
| | - Eva Díaz
- Foundation MD Anderson International, C/Gómez Hemans 2, 28033 Madrid, Spain; (E.D.); (S.S.O.); (G.M.-B.)
| | - Cristian Pablo Moiola
- Biomedical Research Group in Gynecology, Vall d’Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, 119-129 Pg. Vall d’Hebron, 08035 Barcelona, Spain; (C.P.M.); (S.C.); (E.C.); (A.G.-M.)
| | | | - Alba Ferreiros
- Nasasbiotech, S.L., Canton Grande 3, 15003 A Coruña, Spain; (L.A.-A.); (A.F.)
| | - Alicia Abalo
- Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain; (C.C.-A.); (A.A.); (J.C.); (M.A.)
| | - Carlos López Gil
- Biomedical Research Group in Gynecology, Vall d’Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, 119-129 Pg. Vall d’Hebron, 08035 Barcelona, Spain; (C.P.M.); (S.C.); (E.C.); (A.G.-M.)
| | - Sara S. Oltra
- Foundation MD Anderson International, C/Gómez Hemans 2, 28033 Madrid, Spain; (E.D.); (S.S.O.); (G.M.-B.)
| | - Javier de Santiago
- Department of Gynecology, MD Anderson Cancer Center, 28029 Madrid, Spain;
| | - Silvia Cabrera
- Biomedical Research Group in Gynecology, Vall d’Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, 119-129 Pg. Vall d’Hebron, 08035 Barcelona, Spain; (C.P.M.); (S.C.); (E.C.); (A.G.-M.)
| | - Victoria Sampayo
- Department of Gynecology, University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain; (V.S.); (E.A.); (A.V.)
| | - Marta Bouso
- Department of Pathology, University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain;
| | - Efigenia Arias
- Department of Gynecology, University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain; (V.S.); (E.A.); (A.V.)
| | - Juan Cueva
- Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain; (C.C.-A.); (A.A.); (J.C.); (M.A.)
| | - Eva Colas
- Biomedical Research Group in Gynecology, Vall d’Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, 119-129 Pg. Vall d’Hebron, 08035 Barcelona, Spain; (C.P.M.); (S.C.); (E.C.); (A.G.-M.)
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain
| | - Ana Vilar
- Department of Gynecology, University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain; (V.S.); (E.A.); (A.V.)
| | - Antonio Gil-Moreno
- Biomedical Research Group in Gynecology, Vall d’Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, 119-129 Pg. Vall d’Hebron, 08035 Barcelona, Spain; (C.P.M.); (S.C.); (E.C.); (A.G.-M.)
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain
| | - Miguel Abal
- Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain; (C.C.-A.); (A.A.); (J.C.); (M.A.)
- Nasasbiotech, S.L., Canton Grande 3, 15003 A Coruña, Spain; (L.A.-A.); (A.F.)
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain
| | - Gema Moreno-Bueno
- Foundation MD Anderson International, C/Gómez Hemans 2, 28033 Madrid, Spain; (E.D.); (S.S.O.); (G.M.-B.)
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain
- Department of Biochemistry, Autonomic University of Madrid (UAM), Biomedical research Institute ‘Alberto Sols’ (CSIC-UAM), IdiPaz, Arzobispo Morcillo 4, 28029 Madrid, Spain
| | - Laura Muinelo-Romay
- Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706 Santiago de Compostela, Spain; (C.C.-A.); (A.A.); (J.C.); (M.A.)
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Monforte de Lemos 3-5, 28029 Madrid, Spain
| |
Collapse
|
8
|
Hernando B, Ibarrola-Villava M, Oltra SS, Valcuende-Cavero F, Pitarch G, Mahiques L, Ribas G, Martinez-Cadenas C. Sun exposure and PDZK1 genotype modulate PDZK1 gene expression in normal skin. Photodermatol Photoimmunol Photomed 2019; 36:70-72. [PMID: 31444921 DOI: 10.1111/phpp.12508] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/09/2019] [Revised: 06/17/2019] [Accepted: 08/12/2019] [Indexed: 12/21/2022]
Affiliation(s)
- Barbara Hernando
- Department of Medicine, Jaume I University of Castellon, Castellon, Spain
| | - Maider Ibarrola-Villava
- Department of Medical Oncology, Biomedical Research Institute - INCLIVA, Valencia, Spain.,Network Centre for Biomedical Cancer Research (CIBERONC), Biomedical Research Institute - INCLIVA, Valencia, Spain
| | - Sara S Oltra
- Department of Medical Oncology, Biomedical Research Institute - INCLIVA, Valencia, Spain.,Network Centre for Biomedical Cancer Research (CIBERONC), Biomedical Research Institute - INCLIVA, Valencia, Spain
| | - Francisca Valcuende-Cavero
- Department of Dermatology, La Plana University Hospital. Carretera Villarreal-Burriana, Villarreal, Spain
| | - Gerard Pitarch
- Department of Dermatology, Castellon University General Hospital. Ave. Benicassim, Castellon, Spain
| | - Laura Mahiques
- Department of Dermatology, Castellon University General Hospital. Ave. Benicassim, Castellon, Spain
| | - Gloria Ribas
- Department of Medical Oncology, Biomedical Research Institute - INCLIVA, Valencia, Spain.,Network Centre for Biomedical Cancer Research (CIBERONC), Biomedical Research Institute - INCLIVA, Valencia, Spain
| | | |
Collapse
|
9
|
Martínez MT, Oltra SS, Peña-Chilet M, Alonso E, Hernando C, Burgues O, Chirivella I, Bermejo B, Lluch A, Ribas G. Breast Cancer in Very Young Patients in a Spanish Cohort: Age as an Independent Bad Prognostic Indicator. Breast Cancer (Auckl) 2019; 13:1178223419828766. [PMID: 30814839 PMCID: PMC6383086 DOI: 10.1177/1178223419828766] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/17/2018] [Accepted: 12/28/2018] [Indexed: 12/24/2022]
Abstract
Purpose: Breast cancer (BC) in very young women (BCVY) is more aggressive than in
older women. The purpose of this study was to evaluate the relevance of a
range of clinico-pathological factors in the prognosis of BCVY patients. Methods: We retrospectively analyzed 258 patients diagnosed with BCVY at our hospital
from 1998 to 2014; the control group comprised 101 older patients with BC.
We correlated clinicopathological factors, treatments, relapse and exitus
with age and with previously published miRNA expression data. Results: We identified some significant differences in risk factors between BCVY and
older patients. The age at menarche, number of pregnancies, and age at first
pregnancy were lower in the BCVY group and had a greater probability of
recurrence and death in all cases. Lymph node-positive patients in the BCVY
group are associated with a worse prognosis
(P = .02), an immunohistochemical
HER2+ subtype, and disease relapse
(P = .03). Moreover, there was a
shorter time between diagnosis and first relapse in BCVY patients compared
with controls, and they were more likely to die from the disease
(P = .002). Finally, from our panel of
miRNAs deregulated in BC, reduced miR-30c expression was associated with
more aggressive BC in very young patients, lower overall survival, and with
axillary lymph node metastases. Conclusions: Patient age and axillary lymph node status post-surgery are independent and
significant predictors of distant disease-free survival, local
recurrence-free survival, and overall survival. The HER2+ subtype
and lower miR-30c expression are related to poor prognosis in lymph
node-positive young BC patients.
Collapse
Affiliation(s)
- María Teresa Martínez
- Medical Oncology and Hematology Unit, Health Research Institute INCLIVA, Valencia, Spain.,Centre of Networked Biomedical Cancer Research (CIBERONC), Valencia, Spain
| | - Sara S Oltra
- Medical Oncology and Hematology Unit, Health Research Institute INCLIVA, Valencia, Spain.,Centre of Networked Biomedical Cancer Research (CIBERONC), Valencia, Spain
| | - María Peña-Chilet
- Medical Oncology and Hematology Unit, Health Research Institute INCLIVA, Valencia, Spain.,Centre of Networked Biomedical Cancer Research (CIBERONC), Valencia, Spain
| | - Elisa Alonso
- Department of Pathology, Health Research Institute INCLIVA, Valencia, Spain
| | - Cristina Hernando
- Medical Oncology and Hematology Unit, Health Research Institute INCLIVA, Valencia, Spain.,Centre of Networked Biomedical Cancer Research (CIBERONC), Valencia, Spain
| | - Octavio Burgues
- Department of Pathology, Health Research Institute INCLIVA, Valencia, Spain
| | - Isabel Chirivella
- Medical Oncology and Hematology Unit, Health Research Institute INCLIVA, Valencia, Spain.,Centre of Networked Biomedical Cancer Research (CIBERONC), Valencia, Spain
| | - Begoña Bermejo
- Medical Oncology and Hematology Unit, Health Research Institute INCLIVA, Valencia, Spain.,Centre of Networked Biomedical Cancer Research (CIBERONC), Valencia, Spain
| | - Ana Lluch
- Medical Oncology and Hematology Unit, Health Research Institute INCLIVA, Valencia, Spain.,Centre of Networked Biomedical Cancer Research (CIBERONC), Valencia, Spain
| | - Gloria Ribas
- Medical Oncology and Hematology Unit, Health Research Institute INCLIVA, Valencia, Spain.,Centre of Networked Biomedical Cancer Research (CIBERONC), Valencia, Spain
| |
Collapse
|
10
|
Oltra SS, Peña-Chilet M, Vidal-Tomas V, Flower K, Martinez MT, Alonso E, Burgues O, Lluch A, Flanagan JM, Ribas G. Methylation deregulation of miRNA promoters identifies miR124-2 as a survival biomarker in Breast Cancer in very young women. Sci Rep 2018; 8:14373. [PMID: 30258192 PMCID: PMC6158237 DOI: 10.1038/s41598-018-32393-3] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2018] [Accepted: 08/02/2018] [Indexed: 01/02/2023] Open
Abstract
MiRNAs are part of the epigenetic machinery, and are also epigenetically modified by DNA methylation. MiRNAs regulate expression of different genes, so any alteration in their methylation status may affect their expression. We aimed to identify methylation differences in miRNA encoding genes in breast cancer affecting women under 35 years old (BCVY), in order to identify potential biomarkers in these patients. In Illumina Infinium MethylationEPIC BeadChip samples (metEPICVal), we analysed the methylation of 9,961 CpG site regulators of miRNA-encoding genes present in the array. We identified 193 differentially methylated CpG sites in BCVY (p-value < 0.05 and methylation differences ±0.1) that regulated 83 unique miRNA encoding genes. We validated 10 CpG sites using two independent datasets based on Infinium Human Methylation 450k array. We tested gene expression of miRNAs with differential methylation in BCVY in a meta-analysis using The Cancer Genome Atlas (TCGA), Clariom D and Affymetrix datasets. Five miRNAs (miR-9, miR-124-2, miR-184, miR-551b and miR-196a-1) were differently expressed (FDR p-value < 0.01). Finally, only miR-124-2 shows a significantly different gene expression by quantitative real-time PCR. MiR-124-hypomethylation presents significantly better survival rates for older patients as opposed to the worse prognosis observed in BCVY, identifying it as a potential specific survival biomarker in BCVY.
Collapse
Affiliation(s)
- Sara S Oltra
- INCLIVA Biomedical Research Institute, Hospital Clínico Universitario Valencia, University of Valencia, Valencia, Spain
| | - Maria Peña-Chilet
- INCLIVA Biomedical Research Institute, Hospital Clínico Universitario Valencia, University of Valencia, Valencia, Spain
| | - Victoria Vidal-Tomas
- INCLIVA Biomedical Research Institute, Hospital Clínico Universitario Valencia, University of Valencia, Valencia, Spain
| | - Kirsty Flower
- Department of Surgery and Cancer, Imperial College London, London, UK
| | - María Teresa Martinez
- INCLIVA Biomedical Research Institute, Hospital Clínico Universitario Valencia, University of Valencia, Valencia, Spain
| | - Elisa Alonso
- Pathology Department, Hospital Clínico Universitario Valencia, University of Valencia, Valencia, Spain
| | - Octavio Burgues
- Pathology Department, Hospital Clínico Universitario Valencia, University of Valencia, Valencia, Spain
| | - Ana Lluch
- INCLIVA Biomedical Research Institute, Hospital Clínico Universitario Valencia, University of Valencia, Valencia, Spain.,Center for Biomedical Network Research on Cancer, Valencia, Spain
| | - James M Flanagan
- Department of Surgery and Cancer, Imperial College London, London, UK
| | - Gloria Ribas
- INCLIVA Biomedical Research Institute, Hospital Clínico Universitario Valencia, University of Valencia, Valencia, Spain. .,Center for Biomedical Network Research on Cancer, Valencia, Spain.
| |
Collapse
|
11
|
Hernando B, Ibarrola-Villava M, Fernandez LP, Peña-Chilet M, Llorca-Cardeñosa M, Oltra SS, Alonso S, Boyano MD, Martinez-Cadenas C, Ribas G. Sex-specific genetic effects associated with pigmentation, sensitivity to sunlight, and melanoma in a population of Spanish origin. Biol Sex Differ 2016; 7:17. [PMID: 26998216 PMCID: PMC4797181 DOI: 10.1186/s13293-016-0070-1] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/16/2016] [Accepted: 03/07/2016] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND Human pigmentation is a polygenic quantitative trait with high heritability. In addition to genetic factors, it has been shown that pigmentation can be modulated by oestrogens and androgens via up- or down-regulation of melanin synthesis. Our aim was to identify possible sex differences in pigmentation phenotype as well as in melanoma association in a melanoma case-control population of Spanish origin. METHODS Five hundred and ninety-nine females (316 melanoma cases and 283 controls) and 458 males (234 melanoma cases and 224 controls) were analysed. We genotyped 363 polymorphisms (single nucleotide polymorphisms (SNPs)) from 65 pigmentation gene regions. RESULTS When samples were stratified by sex, we observed more SNPs associated with dark pigmentation and good sun tolerance in females than in males (107 versus 75; P = 2.32 × 10(-6)), who were instead associated with light pigmentation and poor sun tolerance. Furthermore, six SNPs in TYR, SILV/CDK2, GPR143, and F2RL1 showed strong differences in melanoma risk by sex (P < 0.01). CONCLUSIONS We demonstrate that these genetic variants are important for pigmentation as well as for melanoma risk, and also provide suggestive evidence for potential differences in genetic effects by sex.
Collapse
Affiliation(s)
- Barbara Hernando
- Department of Medicine, Jaume I University of Castellon, Av. Sos Baynat s/n, 12071 Castellon, Spain
| | - Maider Ibarrola-Villava
- Department of Medical Oncology, Biomedical Research Institute - INCLIVA, University of Valencia, Av. Menendez Pelayo 4 accesorio, 46010 Valencia, Spain
| | - Lara P Fernandez
- Molecular Oncology and Nutritional Genomics of Cancer Group, IMDEA Food Institute, CEI UAM + CSIC, Madrid, Spain
| | - Maria Peña-Chilet
- Department of Medical Oncology, Biomedical Research Institute - INCLIVA, University of Valencia, Av. Menendez Pelayo 4 accesorio, 46010 Valencia, Spain
| | - Marta Llorca-Cardeñosa
- Department of Medical Oncology, Biomedical Research Institute - INCLIVA, University of Valencia, Av. Menendez Pelayo 4 accesorio, 46010 Valencia, Spain
| | - Sara S Oltra
- Department of Medical Oncology, Biomedical Research Institute - INCLIVA, University of Valencia, Av. Menendez Pelayo 4 accesorio, 46010 Valencia, Spain
| | - Santos Alonso
- Department of Genetics, Physical Anthropology and Animal Physiology, University of the Basque Country UPV/EHU, Leioa, Bizkaia Spain
| | - Maria Dolores Boyano
- Department of Cell Biology and Histology, University of the Basque Country UPV/EHU, Leioa, Bizkaia Spain.,BioCruces Health Research Institute, Cruces University Hospital, Cruces-Barakaldo, Bizkaia Spain
| | - Conrado Martinez-Cadenas
- Department of Medicine, Jaume I University of Castellon, Av. Sos Baynat s/n, 12071 Castellon, Spain
| | - Gloria Ribas
- Department of Medical Oncology, Biomedical Research Institute - INCLIVA, University of Valencia, Av. Menendez Pelayo 4 accesorio, 46010 Valencia, Spain
| |
Collapse
|
12
|
Peña-Chilet M, Martínez MT, Pérez-Fidalgo JA, Peiró-Chova L, Oltra SS, Tormo E, Alonso-Yuste E, Martinez-Delgado B, Eroles P, Climent J, Burgués O, Ferrer-Lozano J, Bosch A, Lluch A, Ribas G. MicroRNA profile in very young women with breast cancer. BMC Cancer 2014; 14:529. [PMID: 25047087 PMCID: PMC4223555 DOI: 10.1186/1471-2407-14-529] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2013] [Accepted: 07/15/2014] [Indexed: 12/20/2022] Open
Abstract
Background Breast cancer is rarely diagnosed in very young women (35years old or younger), and it often presents with distinct clinical-pathological features related to a more aggressive phenotype and worse prognosis when diagnosed at this early age. A pending question is whether breast cancer in very young women arises from the deregulation of different underlying mechanisms, something that will make this disease an entity differentiated from breast cancer diagnosed in older patients. Methods We performed a comprehensive study of miRNA expression using miRNA Affymetrix2.0 array on paraffin-embedded tumour tissue of 42 breast cancer patients 35 years old or younger, 17 patients between 45 and 65 years old and 29 older than 65 years. Data were statistically analyzed by t-test and a hierarchical clustering via average linkage method was conducted. Results were validated by qRT-PCR. Putative targeted pathways were obtained using DIANA miRPath online software. Results The results show a differential and unique miRNA expression profile of 121 miRNAs (p-value <0.05), 96 of those with a FDR-value <0.05. Hierarchical clustering grouped the samples according to their age, but not by subtype nor by tumour characteristics. We were able to validate by qRT-PCR differences in the expression of 6 miRNAs: miR-1228*, miR-3196, miR-1275, miR-92b, miR-139 and miR-1207. Moreover, all of the miRNAs maintained the expression trend. The validated miRNAs pointed out pathways related to cell motility, invasion and proliferation. Conclusions The study suggests that breast cancer in very young women appears as a distinct molecular signature. To our knowledge, this is the first time that a validated microRNA profile, distinctive to breast cancer in very young women, has been presented. The miRNA signature may be relevant to open an important field of research in order to elucidate the underlying mechanism in this particular disease, which in a more clinical setting, could potentially help to identify therapeutic targets in this particular set of patients.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Gloria Ribas
- Medical Oncology and Hematology Unit, INCLIVA Biomedical Research Institute, Av, Blasco Ibañez, 17, Valencia 46010, Spain.
| |
Collapse
|